STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma

Cancer Discovery
Ferdinandos SkoulidisJohn V Heymach

Abstract

KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of KRAS-mutant LUAC. Here, we examine the efficacy of PD-1 inhibitors in these subgroups. Objective response rates to PD-1 blockade differed significantly among KL (7.4%), KP (35.7%), and K-only (28.6%) subgroups (P < 0.001) in the Stand Up To Cancer (SU2C) cohort (174 patients) with KRAS-mutant LUAC and in patients treated with nivolumab in the CheckMate-057 phase III trial (0% vs. 57.1% vs. 18.2%; P = 0.047). In the SU2C cohort, KL LUAC exhibited shorter progression-free (P < 0.001) and overall (P = 0.0015) survival compared with KRASMUT;STK11/LKB1WT LUAC. Among 924 LUACs, STK11/LKB1 alterations were the only marker significantly associated with PD-L1 negativity in TMBIntermediate/High LUAC. The impact of STK11/LKB1 alterations on clinical outcomes with PD-1/PD-L1 inhibitors extended to PD-L1-positive non-small cell lung cancer. In Kras-mutant murine LUAC models, Stk11/Lkb1 loss promoted PD-1/PD-L1 inhibitor resistance, suggesting a causal role. Our results identify STK11/LKB1 alterations as a major driver of primary resistance to PD-1 blockade in KRAS-mutant LU...Continue Reading

References

Jul 25, 2009·Nature Reviews. Cancer·David B Shackelford, Reuben J Shaw
Oct 27, 2010·The Journal of Biological Chemistry·Anita MorénAristidis Moustakas
Jan 30, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hao TangYang Xie
Sep 21, 2013·Nature Immunology·Thomas F GajewskiYang-Xin Fu
Aug 1, 2014·Nature·UNKNOWN Cancer Genome Atlas Research Network
Nov 11, 2014·Nature Medicine·Zongli ZhengLong Phi Le
Nov 20, 2014·The New England Journal of Medicine·Alexandra SnyderTimothy A Chan
Nov 22, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Helena A YuGregory J Riely
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
May 15, 2015·Nature·Stefani SprangerThomas F Gajewski
May 28, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Funda Meric-BernstamGordon B Mills
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Sep 12, 2015·Science·Eliezer M Van AllenLevi A Garraway
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Dec 10, 2015·Cancer Discovery·Weiyi PengPatrick Hwu
Apr 16, 2016·Nature Reviews. Cancer·Suzanne L TopalianDrew M Pardoll
Oct 1, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H KadaraR S Herbst
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Nov 4, 2016·Nature·Filippos KottakisNabeel Bardeesy
Jan 26, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Laura BonannoStefano Indraccolo
Apr 20, 2017·Genome Medicine·Zachary R ChalmersGarrett M Frampton
Jun 22, 2017·The New England Journal of Medicine·David P CarboneUNKNOWN CheckMate 026 Investigators
Oct 13, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leora HornWilfried E E Eberhardt
Nov 2, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kathryn C ArbourGregory J Riely
Dec 2, 2017·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Francesco FacchinettiBenjamin Besse
Dec 2, 2017·Cell·Roderik M KortleverGerard I Evan

❮ Previous
Next ❯

Citations

Sep 7, 2018·Nature Biotechnology·Cormac Sheridan
Nov 6, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T A ChanS Peters
Nov 1, 2018·British Journal of Cancer·Francesco PassigliaDomenico Galetta
Feb 19, 2019·Cancer Medicine·Priyanka BhatejaAfshin Dowlati
Jan 18, 2019·International Journal of Cancer. Journal International Du Cancer·Anna-Lena VolckmarAlbrecht Stenzinger
Oct 31, 2018·Virchows Archiv : an International Journal of Pathology·Alessandra TuccittoViviana Vallacchi
May 14, 2019·Expert Review of Molecular Diagnostics·Ke MaYuyang Zhang
Jul 11, 2019·Nature Reviews. Clinical Oncology·Anita SveenRagnhild A Lothe
May 28, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J MazieresO Gautschi
Feb 23, 2019·ESMO Open·Reinhard BüttnerFrédérique Penault-Llorca
Jun 25, 2019·ESMO Open·Gema BruxiolaAndrés Cervantes
Jul 31, 2019·International Journal of Cancer. Journal International Du Cancer·Kristin GurtnerMechthild Krause
Aug 14, 2019·Archives of Pathology & Laboratory Medicine·Eric H Bernicker
Dec 12, 2018·Current Cancer Drug Targets·Tatsuya NaganoYoshihiro Nishimura
Dec 6, 2019·Journal of Cellular Biochemistry·James L MulshineJohn D Minna
Jan 19, 2020·International Journal of Molecular Sciences·Sanna Iivanainen, Jussi P Koivunen
Sep 25, 2019·Nature Reviews. Clinical Oncology·Michael J TopperStephen B Baylin
Jan 28, 2020·Annual Review of Medicine·Ching-Yao YangPan-Chyr Yang
Nov 22, 2019·The Oncologist·Jacob J AdashekRazelle Kurzrock
Mar 7, 2020·Expert Review of Anticancer Therapy·Edgardo S Santos
Apr 5, 2020·International Journal of Molecular Sciences·Shunsuke KitajimaChiaki Takahashi
Apr 22, 2020·American Society of Clinical Oncology Educational Book·Galina G LagosNaiyer A Rizvi
Apr 23, 2020·Expert Review of Anticancer Therapy·Dimitra Grapsa, Konstantinos Syrigos
Jun 23, 2020·Pharmacogenomics·Sylvie Brassart-PascoJean-Baptiste Oudart
Jun 6, 2020·Future Oncology·Maria Virginia BluthgenGonzalo Recondo
May 27, 2020·Médecine sciences : M/S·Nicolas GuibertJulien Mazières
Aug 29, 2020·Journal of Cancer Research and Clinical Oncology·Laiyan ZhouYou Lu
Sep 2, 2020·Expert Review of Anticancer Therapy·Friedlaender Alex, Addeo Alfredo
Sep 5, 2020·Cancer Cytopathology·Paul A VanderLaan, Sinchita Roy-Chowdhuri
Sep 6, 2020·Genome Research·Yoshitaka SakamotoYutaka Suzuki
Sep 17, 2020·ESMO Open·Nikki Burdett, Jayesh Desai
Apr 3, 2020·The Journal of Experimental Medicine·Grinu Mathew, Lloyd C Trotman
Sep 14, 2018·The New England Journal of Medicine·Paul A VanderLaanDaniel B Costa
Nov 18, 2018·Journal of Evidence-based Medicine·Jingsi DongDepei Huang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.